A Phase 1/2a Open Label Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults
Phase of Trial: Phase I/II
Latest Information Update: 02 Apr 2019
Price : $35 *
At a glance
- Drugs PGDM1400 (Primary) ; PGT 121 (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 25 Mar 2019 PGDM1400 drug has been added in the study hence treatment, offitial title and primary outcome has also changed.
- 25 Mar 2019 Planned number of patients changed from 21 to 18.
- 18 Dec 2018 Status changed from not yet recruiting to recruiting.